# US 2012/0269843 A1 · S. epidermidis antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269843 A1
- Document ID: US20120269843A1
- Status: Published application
- Kind: A1
- Application number: 13/540,696
- Filed: 2012-07-03
- Published: 2012-10-25
- Earliest claimed: 2003-03-31
- Assignees: Intercell AG
- Inventors: Andreas Meinke; Duc Min Bui; Eszter Nagy
- Web page: https://patentgrep.com/patent/US20120269843A1

## CPC

- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/31: from Staphylococcus (G)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55516: {Proteins; Peptides}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of S. epidermidis infections, are disclosed.

## Claims

### Claim 1

An isolated hyperimmune serum-reactive antigen consisting of a fragment of SEQ ID NO: 56, wherein said fragment comprises an amino acid sequence selected from the group consisting of amino acids 4-21, 29-42, 48-62, 65-80, 95-101, 103-118, 122-130, 134-140, 143-152, 155-165, 182-192, 198-208, 232-247, 260-268, 318-348, 364-369, 380-391, 403-411 and 413-424 of SEQ ID NO: 56, and wherein said fragment is less than 442 amino acids in length.

### Claim 2 (depends on 1)

An immunogenic composition comprising the isolated hyperimmune serum-reactive antigen of claim 1.

### Claim 3 (depends on 2)

The immunogenic composition of claim 2, comprising at least 2 different hyperimmune serum-reactive antigens.

### Claim 4 (depends on 2)

The immunogenic composition of claim 2, further comprising an adjuvant.

### Claim 5 (depends on 3)

The immunogenic composition of claim 3, further comprising an adjuvant.

### Claim 6 (depends on 1)

A fusion protein comprising the hyperimmune serum-reactive antigen according to claim 1.

### Claim 7 (depends on 6)

An immunogenic composition comprising the fusion protein of claim 6.

### Claim 8 (depends on 7)

The immunogenic composition of claim 7, further comprising an adjuvant.

### Claim 9 (depends on 2)

A method of inducing an immune response in a subject comprising:
administering the immunogenic composition of claim 2 to a subject;
wherein an immune response is induced in the subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the subject is a human.

### Claim 11 (depends on 9)

The method of claim 9, wherein the subject has an S. epidermidis infection.

### Claim 12 (depends on 7)

A method of inducing an immune response in a subject comprising:
administering the immunogenic composition of claim 7 to a subject;
wherein an immune response is induced in the subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject is a human.

### Claim 14 (depends on 12)

The method of claim 12, wherein the subject has an S. epidermidis infection.
